Summary In small-cell lung cancer cell lines resistance to growth inhibition by transforming growth factor (TGF)-f,, was previously shown to correlate with lack of TGF-,B receptor I (RI) and II (RII) proteins. To further investigate the role of these receptors, the expression of mRNA for RI, RII and beta-glycan (RIII) was examined. The results showed that loss of RII mRNA correlated with TGF-3,B resistance. In contrast, RI-and beta-glycan mRNA was expressed by all cell lines, including those lacking expression of these proteins. According to Southern blot analysis, the loss of type II mRNA was not due to gross structural changes in the gene. The effect of TGF-fl, on expression of TGF-,B receptor mRNA (receptor autoregulation) was examined by quantitative Northern blotting in four cell lines with different expression of TGF-fl receptor proteins. In two cell lines expressing all three TGF-fl receptor proteins beta-glycan mRNA was rapidly down-regulated and this effect was sustained throughout the 24 h observation period. RI and RII mRNAs were slightly increased 24 h after treatment. In one cell line sensitive to growth inhibition by TGF-fi,, but lacking beta-glycan expression, and one cell line expressing only beta-glycan and thus TGF-f,B-resistant, no autoregulation of mRNA of either TGF-,B receptor was demonstrated. The results suggest that TGF-fl, regulates the expression of its receptors, in particular beta-glycan, and that this effect is dependent on co-expression of beta-glycan, RI and RII.
Transforming growth factor /B (TGF-fl) is the prototype polypeptide growth factor of the TGF-,B superfamily, which also includes e.g. the activins, inhibins and bone morphogenetic protein (Massague, 1990) . TGF-# acts in a paracrine and autocrine fashion as a multifunctional growth factor, influencing basic cellular functions such as proliferation, differentiation, cell-cell and cell-matrix interaction (Roberts and Sporn, 1990; Moses, 1992; Kingsley, 1994) . Three isoforms TGF-/,3, TGF-f32 and TGF-/33, are expressed by many human cell types; TGF-3,B is the most widely studied.
In mammalian cells the TGF-# isoforms bind with high affinity and specificity to three transmembrane receptors (type I, II and beta-glycan), which are expressed by a wide range of normal and malignant cells (Attisano et al., 1994; N0rgaard et al., 1995) . Type I (RI) and type II (RII) receptors are structurally analogous glycoproteins with an intracellular serine/threonine kinase domain. They are considered to be the signaltransducing TGF-# receptors, as both receptors are required for mediating the various effects of TGF-,B (Wrana et al., 1992 (Wrana et al., , 1994 .
TGF-,B, has a strong growth inhibitive effect in vitro on most ectodermally derived cell types (N0rgaard et al., 1995) . In small-cell lung cancer (SCLC) cell lines, resistance to growth inhibition by TGF-f,, correlated with lack of RI and RII protein (N0rgaard et al., 1994) , and in other human cancer cell lines with decreased or loss of RII protein expression (Geiser et al., 1992; Inagaki et al., 1993; Park et al., 1994) . Very recently it was described that in colon cancer cell lines loss of RII mRNA and protein owing to mutations within small repeated sequences of the RII gene correlated with DNA repair defects (Markowitz et al., 1995) . The role of RI expression is less defined due to the fact that this receptor only binds TGF-,B in the presence of RII (Laiho et al., 1991; Inagaki et al., 1993) . Hence, RI cannot be detected by ligand-binding assays (e.g. chemical cross-linking assay) unless co-expressed with RII. Recently, cDNAs for human RI and RII were cloned. Several different human RI receptor cDNAs were identified (Attisano et al., 1993; Franzen et al., 1993; ten Dijke et al., 1994) . Some of these had the capacity to bind the different members of the TGF-,B superfamily, depending on the type of RII with which they were coexpressed (Ebner et al., 1993a; Attisano et al., 1993; ten Dijke et al., 1994) . However only one RI, termed ALK-5, has been shown to respond to TGF-1l3 binding with serine/threonine kinase activity and to restore TGF-f, response upon transfection into RI-defective cells (Franzen et al., 1993) . In contrast to RI, only one RII has been found (Lin et al., 1992) .
Beta-glycan, also termed type III TGF-# receptor, is a proteoglycan, which is structurally different from the type I and II receptors. It has a relatively large extracellular part, and a short cytoplasmic part, which apparently lacks a catalytic domain (Lopez-Casillas et al., 1991; Wang et al., 1991; Moren et al., 1992) . Accordingly several cell types are responsive to TGF-,B despite lacking beta-glycan (Wang et al., 1991; Boyd and Massague, 1989; N0rgaard et al., 1994; Lopez-Casillas et al., 1993) , but in some cases the presence of beta-glycan in these cells increased the binding of TGF-f to RII. Beta-glycan is therefore thought to function as a ligand capacitor, regulating the amount of ligand available for the signalling receptors RI and RII.
TGF-f3, may exert its growth-inhibitory effect in part by regulating the expression of other polypeptide growth factors and their receptors (Assoian et al., 1984; Massague, 1985) . TGF-13, was also shown to induce its own expression (Van Obberghen-Schilling et al., 1988) , but whether the expression of TGF-,B receptors is regulated by B (autoregulation) has not yet been described.
In this study we characterised the expression of mRNA for RI and RII and beta-glycan in a panel of nine SCLC cell lines previously examined for TGF-J,A sensitivity (N0rgaard et al., 1994) and with different expression of TGF-# receptor proteins (Damstrup et al., 1993 (GLC 3, GLC 16, GLC 19) were allowed to sediment before replacing the medium.
All cell lines were routinely checked for, and found free of, mycoplasma infection.
For steady-state mRNA expression studies subconfluent, exponentially growing cells were harvested using a cell scraper and centrifuged at 1100 g. The cell pellet was frozen immediately in liquid nitrogen and stored at -70°C until analysis.
Growth factor treatment assay Porcine TGF-/, was purchased from R&D Systems Europe, Oxon, UK. Dried TGF-/3, (1 pg) was reconstitued in 0.5 ml of 4 mm hydrochloric acid containing 2 mg ml-' bovine serum albumin and stored at 4°C. For Cycloheximide treatment Where indicated, 10 jug ml-1 cycloheximide (Sigma, St Louis, MO, USA) dissolved in PBS was added to the culture medium alone or in combination with TGF-,B,, and cells were harvested as described above after 4 and 24 h.
RNA extraction, electrophoresis and blotting PolyA+ RNA as extracted directly from the frozen (-70°C) cell pellets by the guanidinium thiocyanate method followed by two sequential purifications by oligo(dT)-cellulose chromatography using a commercial kit (QuickPrep mRNA Purification Kit, Pharmacia) (Chirgwin et al., 1979) . The concentration was determined by spectrophotometry, and the RNA was precipitated under ethanol at -70°C, in aliquots of 3-5 pg. The RNA was dissolved in sample buffer (50% formamide, 2.2 M formaldehyde, 20 mM 3-morpholino-propane-sulphonic acid, 5 mm sodium acetate, 1 mM EDTA, 2% Ficoll 400, 0.25% bromophenol blue) containing 0.033 g p l-' ethidium bromide and electrophoresed under denaturing conditions in 1 % agarose gels containing 2.2 M formaldehyde, together with 5 pg RNA size marker (RNA ladder, Gibco BRL). Transfer to charged nylon membranes (Gene Screen Plus, NEN DuPont) was done in 10 x saline sodium citrate (1 x saline sodium citrate = 150 mm sodium chloride, 15 mM sodium citrate). The Northern blots were prehybridised for at least 3 h and hybridised for 18 h at 42°C in a buffer containing 50% formamide, 1% sodium dodecylsulphate, 1 M sodium chloride, 5% dextran sulphate, 100 pg ml-' denatured salmon testes DNA. Maximal washing stringency was 65°C in 2 x saline sodium citrate, 1% sodium dodecylsulphate.
For determination of steady-state mRNA expression Northern blots were exposed to X-ray film (Amersham) at -80°C with an intensifying screen for 1 -7 days. The blots were hybridised and rehybridised with the three TGF-,B receptor probes, followed by the glyceraldehyde-3 phosphate dehydrogenase (GAPDH) probe, which was used as an internal standard to compare the amounts of polyA+ RNA transferred to the membranes.
RNA quantification
In order to minimise loss of mRNA from the membranes during the high stringency wash performed to strip off the probes, Northern blots for quantitative measurements were used for only one hybridisation with a TGF-,B receptor probe and subsequently reprobed with the GAPDH standard probe. The hybridised Northern blots were analysed on a phosphorimager (Molecular Dynamics). The amounts of receptor mRNA were normalised against the corresponding amounts of GAPDH mRNA, which was found to be unaffected by TGF-fl1 (Edwards et al., 1985) . The normalised amounts of TGF-fB receptor mRNA in cells treated with TGF-,B, were expressed relative to the respective mRNA amounts of the corresponding untreated cells (per cent of control). The differences in expression levels were evaluated by the Student's t-test (significance level; P< 0.05). After phosphorimager analysis autoradiography of the blots as performed as described above, with the purpose of photo reproduction. DNA extraction, electrophoresis and blotting DNA was extracted with phenol and chloroform by standard methods (Sambrook et al., 1989) . Digestion with restriction endonucleases BamHI or PstI was performed as recommended by the supplier (Gibco BRL, Life Technologies Europe). Aliquots of 10 ig/lane were electrophoresed in 0.8% agarose gels and transferred to charged nylone membranes (Gene Screen Plus, NEN DuPont). Prehybridisation, hybridisation and washing were as recommended by the supplier: washing stringency was 2 x saline sodium citrate-1% sodium dodecylsulphate twice for 30 min at 60°C. Southern blots were reprobed with a human GAPDH probe. Membranes were exposed to X-ray film (Amersham) at -80°C with an intensifying screen for 7 days. Probes Two RI probes were used. One was a 960 bp EcoRI fragment of the cloned 2.3 kb ALK-5 human cDNA kindly provided by K Miyazono (Franzen et al., 1993) . The other was the full length (2.4 kb EcoRI insert) Tsk-7L murine cDNA kindly provided by R Ebner (Ebner et al., 1993b) . The RII probe was a 930 bp PstI-SacI fragment of the cloned 4.5 kb H2-3FF human cDNA kindly provided by HY Lin (Lin et al., 1992) . The probe for beta-glycan was a 1.1 kb PstI fragment of the cloned 4.2 kb TIIIR-2 human cDNA kindly provided by K Miyazono (Moren et al., 1992) . The human GAPDH probe was a 1.1 kb cDNA fragment purchased from Clontech (Palo Alto, CA, USA), hybridising to a 1.4 kb mRNA. Isolation of cDNA probes was done by standard methods (Sambrook et al., 1989) . Radiolabelled probes were prepared by the random priming method (Feinberg and Vogelstein, 1983 ) using a commercial kit and [x_-32P]dCTP (both from Amersham).
Results
Steady-state TGF-,B receptor mRNA expression The steady-state expressions of TGF-,B receptor mRNA of the examined SCLC cell lines were analysed by Northern blotting. All nine cell lines expressed a single -6.5 kb RI mRNA (ALK-5) and a single -7.0 kb mRNA for betaglycan, whereas only six cell lines expressed a -5.5 kb RII mRNA (Figure 1 CPH 54A and 54B express all three TGF-,B receptors at the mRNA and protein levels ( Figure 1 and Table I ).
Treatment of these cell lines with TGF-/,3 resulted in a statistically significant increase in expression of RI and RII mRNA detected after 24 h of treatment (Figures 2 and 3) . RI mRNA was increased approximately 3-fold, whereas RII mRNA was increased about 2-fold compared with control levels. The responses were very similar in the two cell lines. CPH 54A and 54B also expressed mRNA for another RI, Tsk-7L (Ebner et al., 1993b) , which is the murine homologue and 54B was reduced by TGF-f,B (Figures 2 and 3 ). The reduction 4 h after treatment was more pronounced in CPH 54B than in 54A, but in both cell lines maximal inhibition was 30-40% of the level of untreated cells. The inhibition of beta-glycan mRNA was sustained throughout the 24 h observation period (Figures 2 and 3) . GLC 19 lacks beta-glycan expression at the protein level, but expresses mRNA for all three receptors, and GLC 3 expresses only beta-glycan at the protein level (Table I) .
When these cells were treated with TGF-fl1, no statistically significant modulation of TGF-,B receptor mRNA was observed. In GLC 19 RII mRNA showed a slight decreasing tendency, which was, however, not statistically significant throughout the experiment (Figure 3 ). As indicated with asterisks in Figure 3 minor changes in RII mRNA expression in CPH 54A, 54B and GLC 19 were observed during the first 8 h, and a slight decrease in beta-glycan expression was seen in GLC 3. The limited magnitude and extension of these changes, however, suggest that they represent methodological artefacts.
Effect of cycloheximide on beta-glycan mRNA level
To test whether protein synthesis was required for the observed down-regulation of the beta-glycan mRNA level (Figure 3) , CPH 54A was incubated for 4 or 24 h with cycloheximide (10 jug ml-') alone or in combination with 400 pM TGF-p1. Quantitative Northern blot analysis showed that cycloheximide by itself reduced beta-glycan mRNA, but in a less pronounced way than TGF-fi, after 4 h treatment (Figure 4) . Four hours' cycloheximide treatment antagonised the TGF-fl1 effect. After 24 h cycloheximide markedly reduced beta-glycan mRNA both alone and in combination with TGF-13l.
Discussion
We previously found that sensitivity to the growth-inhibitory effect of TGF-fl, correlated with expression of RI and RII proteins, in a panel of nine SCLC cell lines (N0rgaard et al., 1994) . TGF-f receptors in these cell lines were determined by chemical cross-linking of radiolabelled TGF-fl, (Damstrup et al., 1993) , and as RI only binds TGF-fJ1 when co-expressed with RII (Laiho et al., 1991; Inagaki et al., 1993) , these data could not exclude the possibility that some of the 'RIInegative' cell lines in fact expressed RI.
We therefore studied the expression of mRNA for the TGF-f5 receptors in the panel of SCLC cell lines, and found a correlation between expression of RII mRNA and sensitivity to TGF-fl, (Table I) . RI and beta-glycan mRNAs were expressed by all cell lines examined, including the cell lines in which these receptor proteins were not detected (Table I) , thus there was no correlation between expression of RI or beta-glycan mRNA and sensitivity to growth inhibition by TGF-fl, ( Previously only three reports have described the genetic background for loss of RII in human cancer cells. In one study a panel of colon cancer cell lines was found to harbour mutations in the RII gene, resulting in absent or low levels of RII transcripts and resistance to TGF-,B growth inhibition (Markowitz et al., 1995) . There was a highly significant correlation between escape from the growthinhibitive effect of TGF-j and microsatellite instability resulting in DNA repair defects. In gastric cancer cell lines (Park et al., 1994) and human T-cell malignancy (Kadih et al., 1994) TGF-# resistance was likewise due to altered RII mRNA, caused by amplifications or deletions of the RII gene. Our demonstration of lack of RII mRNA as the cause of TGF-1l3 resistance in SCLC, together with the finding that 16/21 SCLC cell lines lack RI and RII proteins (Damstrup et al., 1993) , add to an emerging picture of a frequent defect of importance in growth regulation in cancer. In agreement with this, we found no signs of deletion or translocation of the RII gene by Southern blotting (data not shown), indicating that the lack of RII mRNA in SCLC could be due to point mutations or silenced transcription.
For RI and beta-glycan we demonstrated a discrepancy between mRNA and protein expression (Table I) . This opens the possibility that RI protein was in fact expressed by the 'RII-negative' cell lines, but inaccessible to detection by the chemical cross-linking assay, as earlier demonstrated in human hepatoma cell lines (Inagaki et al., 1993) and mink lung cells (Laiho et al., 1991) . Four cell lines expressed betaglycan mRNA despite lack of beta-glycan protein expression (Table I ). We could conclude that no deletion or translocation of the beta-glycan gene had occurred in these cell lines, since they all expressed a -7.0 kb transcript (Figure 1) Massague, 1985) , platelet-derived growth factor (Leof et al., 1986; Win et al., 1993) and fibroblast growth factor (Kikuchi et al., 1992) . In addition, TGF-/31 was shown to increase, i.e. autoregulate, its own expression (Van Obberghen-Schilling et al., 1988) . As control of TGF-,B receptor expression determines cellular responsiveness to TGF-fi1, we wanted to examine whether TGF-,B receptor expression was also autoregulated. In this study we used quantitative Northern blotting to demonstrate autoregulation of RI, RII and beta-glycan mRNAs in two cell lines, CPH 54A and 54B, which expressed all three receptor proteins (Table I ). In two cell lines, GLC 19, expressing only RI and RII proteins, and GLC 3 expressing only beta-glycan, autoregulation of TGF-,B receptor mRNA could not be demonstrated (Figure 3 ). TGF-,B receptor autoregulation observed in CPH 54A and 54B ( Figure 3) followed a distinct pattern, where beta-glycan expression was reduced after 4 h and throughout the 24 h treatment period followed by a slight increase of RI and RII expression after 24 h. Beta-glycan is dispensable for mediation of TGF-j31 growth inhibition in many cell types including SCLC (N0rgaard et al., 1994) , but apparently plays a role for binding of TGF-,B to RII (Wang et al., 1991; L6pez-Casillas et al., 1993) . In CPH 54A and 54B beta-glycan provides more than 75% of the TGF-3,B binding sites (unpublished data). Considering that observed mRNA down-regulation is reflected at the protein level, it would have a considerable impact on cellular TGF-/3, binding, towards a net decline in ligand available for the signalling receptors. We in fact observed a decline in TGF-fl, binding in CPH 54A, when this cell line, which expresses high levels of TGF-,B,, was allowed to condition the culture supernatant for more than 2 days (unpublished data).
Co-treatment of CPH 54A with the protein synthesis inhibitor cycloheximide reduced the TGF-3, effect on betaglycan mRNA (Figure 4) signalling receptors. However. despite the fact that the assay used is sensitive and the increases in mRNA expression w-ere statisticall1 significant. the biological meaning of this observation is uncertain because of the limited degree of expression induction. However. autoregulation of a type I TGF-# receptor has also been demonstrated recently in human hepatoma cell lines (Inagaki et al.. 1994) . It was shown that the expression of an RI (SKR-1) was rapidly and stronglv increased, whereas RII mRNA was unaffected bv TGF-#1. The autoinduction of this RI. which is the human homologue of Tsk-7L and capable of binding both TGF-f and activin. agrees with our findings in SCLC The different findings concerning RII autoregulation could be explained by differences in the assays employed. Quantification of receptor mR,NA in the hepatoma cell line was performed by visual interpretation of Northem blots of total RNA. This method is less sensitive than the phosphorimager analysis of blots of polvA-selected RNA used in the present study.
Our data suggest that TGF-fl, regulates the expression of its own receptors. in particular beta-glycan. and that this autoregulation is dependent on expression at the protein level of both beta-glycan. and the signalling receptors RI and RII. This was supported by the finding that TGF-f receptor mRNAs were not autoregulated in GLC 19. despite the fact that this cell line had previously been shown to be sensitive to growth inhibition by TGF-1i3 (N0rgaard et al.. 1994) and to express TGF-13, (unpublished data).
Ligand-induced complex formation betw-een RI and RII and beta-glycan has been demonstrated in other cell types (L6pez-Casillas et al.. 1993 : Inagaki et al.. 1993 Moustakas et al.. 1993 . and the present demonstration of interdependent receptor autoregulation could represent a functional extension of these data. Abbreviations GAPDH; lx-ceraldehyde-3 phosphate dehydrogenase: SCLC.
small-cell lung cancer: TGF-f. transforming growth factor f.
